Compare SENS & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SENS | EOLS |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.9M | 500.0M |
| IPO Year | 2014 | 2018 |
| Metric | SENS | EOLS |
|---|---|---|
| Price | $7.97 | $7.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $13.67 | ★ $15.00 |
| AVG Volume (30 Days) | 621.9K | ★ 622.8K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | N/A | ★ N/A |
| Revenue | $16,389,000.00 | ★ $297,176,000.00 |
| Revenue This Year | $82.21 | $12.44 |
| Revenue Next Year | $55.63 | $17.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.85 | 11.61 |
| 52 Week Low | $4.79 | $3.86 |
| 52 Week High | $10.64 | $9.31 |
| Indicator | SENS | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 34.55 | 41.13 |
| Support Level | $7.35 | $7.07 |
| Resistance Level | $8.49 | $7.28 |
| Average True Range (ATR) | 0.47 | 0.32 |
| MACD | -0.27 | -0.05 |
| Stochastic Oscillator | 4.33 | 17.62 |
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.